RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virus(European Journal of Pharmaceutics and Biopharmaceutics June 2024) ".. Importantly, squential administration of the investigational agents (priming with the vector) further enhanced the anti-cancer efficacy in 3D culture over other groups tested. Taken together, these results support further evaluation of the virus in combination with anti-PD-1 and PTX for the treatment of triple-negative breast cancer patients."
https://www.sciencedirect.com/science/article/pii/S0939641124001267?dgcid=rss_sd_all
Correspondingly – from April 02, 2024 - Study reveals immune cell levels as prognostic marker in early-stage triple-negative breast cancer (TNBC)
Immune cells, also known as tumor-infiltrating lymphocytes, or TILs, are naturally existing immune system cells that can move from the bloodstream into a tumor and can recognize and destroy cancer cells.
" This is an important finding because it highlights that the abundance of TILs in breast tissue is a prognostic biomarker in people with early-stage triple-negative breast cancer, even when chemotherapy is not administered. The study's findings may inspire future clinical trials to explore whether patients with a favorable prognosis (high TILs) can avoid intensive chemotherapy regimens." -- according to Roberto Leon-Ferre, M.D., breast medical oncologist at Mayo Clinic Comprehensive Cancer Center and first author of the study.
The results of this study could lead to a recommendation to include TILs in the pathology reports of early-stage TNBC worldwide, as it has the potential to inform clinicians and patients when they discuss treatment options," says Dr. Salgado.
Furthermore, this biomarker would only require a visual evaluation by a pathologist looking through a microscope, meaning there are no additional costs associated with identifying the presence of immune cells. This could be particularly beneficial to regions with limited resources, adds Dr. Leon-Ferre.
ONCY has identified TiLs as a biomarker and has demonstrated pelareorep's ability to enhance levels of TILS in the tumor microenvironment (TME) thus facilitating the killing of cancer cells including those in TNBC.
https://www.news-medical.net/news/20240402/Study-reveals-immune-cell-levels-as-prognostic-marker-in-early-stage-triple-negative-breast-cancer.aspx